Barbara Eichhorst, MD from University of Cologne, Cologne, Germany discussing treatment options for co-morbid chronic lymphocytic leukemia (CLL) patients. These individuals face frequent medical problems which have to be taken into consideration when choosing a treatment regimen. Dosage reduced treatment should be considered as an option, for example fludareabine plus cyclophosphamide plus rituximab. Another combination that has shown promising responses is bendamustine plus rituximab. Recorded at the European Hematology Association (EHA) 2016 Annual Congress in Copenhagen, Denmark.
Treatment options for co-morbid chronic lymphocytic leukemia (CLL) patients
